Next earnings date: 5 Nov 2025
Novo Nordisk A/S – NYSE:NVO
Novo Nordisk A/S stock price today
$54.32
-33.05
-37.83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Novo Nordisk A/S stock price monthly change
-38.51%
month
Novo Nordisk A/S stock price quarterly change
-38.51%
quarter
Novo Nordisk A/S stock price yearly change
-15.73%
year
Novo Nordisk A/S key metrics
Market Cap | 370.95B |
Enterprise value | 2.08T |
P/E | 29.37 |
EV/Sales | 7.70 |
EV/EBITDA | 15.33 |
Price/Sales | 7.70 |
Price/Book | 23.08 |
PEG ratio | -2.83 |
EPS | 19.97 |
Revenue | 244.24B |
EBITDA | 123.30B |
Income | 89.27B |
Revenue Q/Q | 22.45% |
Revenue Y/Y | 29.71% |
Profit margin | 35.01% |
Oper. margin | 43.96% |
Gross margin | 84.66% |
EBIT margin | 43.96% |
EBITDA margin | 50.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNovo Nordisk A/S stock price history
Novo Nordisk A/S stock forecast
Novo Nordisk A/S financial statements
Average Price Target
$158
Potential upside: 190.86%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 54.3B | 19.42B | 35.78% |
|---|---|---|---|
| Sep 2023 | 58.73B | 22.47B | 38.27% |
| Dec 2023 | 65.86B | 21.96B | 33.35% |
| Mar 2024 | 65.34B | 25.40B | 38.88% |
| 2024-11-06 | 0.91 | 0.9 |
|---|
1.65%
Yield TTM
| Payout ratio | 46.6% |
|---|
| 2019 | 2.12% |
|---|---|
| 2020 | 2.03% |
| 2021 | 1.28% |
| 2022 | 1.19% |
| 2023 | 1.01% |
| Jun 2023 | 280753000000 | 190.28B | 67.77% |
|---|---|---|---|
| Sep 2023 | 300101000000 | 207.11B | 69.01% |
| Dec 2023 | 314486000000 | 207.92B | 66.12% |
| Mar 2024 | 298921000000 | 200.01B | 66.91% |
| Jun 2023 | 28.57B | -9.28B | -12.58B |
|---|---|---|---|
| Sep 2023 | 40.96B | -13.24B | -19.83B |
| Dec 2023 | 9.55B | -14.71B | -10.11B |
| Mar 2024 | 14.31B | 3.95B | -26.38B |
Novo Nordisk A/S alternative data
Novo Nordisk A/S Social Media Accounts
What are followers?
+1.22%
month
| May 2025 | 142048 |
|---|---|
| Jul 2025 | 146737 |
| Aug 2025 | 148530 |
+0.07%
month
+2.66%
quarter
| Sep 2023 | 731224 |
|---|
Novo Nordisk
| 5 Feb 2023 | 43 |
|---|---|
| 12 Feb 2023 | 44 |
| 19 Feb 2023 | 38 |
| 26 Feb 2023 | 41 |
| 5 Mar 2023 | 42 |
| 12 Mar 2023 | 41 |
| 19 Mar 2023 | 45 |
| 26 Mar 2023 | 39 |
| 2 Apr 2023 | 39 |
| 9 Apr 2023 | 39 |
| 16 Apr 2023 | 42 |
| 23 Apr 2023 | 48 |
| 30 Apr 2023 | 43 |
| 7 May 2023 | 40 |
| 14 May 2023 | 41 |
| 21 May 2023 | 41 |
| 28 May 2023 | 39 |
| 4 Jun 2023 | 30 |
| 11 Jun 2023 | 31 |
| 18 Jun 2023 | 42 |
Novo Nordisk's Sectors
| 5 Feb 2023 | 3 | 30 | 73 | 39 |
|---|---|---|---|---|
| 12 Feb 2023 | 3 | 37 | 78 | 39 |
| 19 Feb 2023 | 4 | 39 | 81 | 42 |
| 26 Feb 2023 | 3 | 42 | 84 | 42 |
| 5 Mar 2023 | 5 | 43 | 83 | 39 |
| 12 Mar 2023 | 3 | 44 | 80 | 44 |
| 19 Mar 2023 | 4 | 37 | 82 | 41 |
| 26 Mar 2023 | 2 | 35 | 77 | 36 |
| 2 Apr 2023 | 3 | 37 | 75 | 39 |
| 9 Apr 2023 | 5 | 37 | 76 | 33 |
| 16 Apr 2023 | 2 | 37 | 73 | 37 |
| 23 Apr 2023 | 2 | 43 | 84 | 37 |
| 30 Apr 2023 | 3 | 38 | 79 | 35 |
| 7 May 2023 | 4 | 30 | 71 | 31 |
| 14 May 2023 | 2 | 37 | 77 | 37 |
| 21 May 2023 | 4 | 38 | 72 | 34 |
| 28 May 2023 | 0 | 35 | 66 | 32 |
| 4 Jun 2023 | 3 | 25 | 54 | 21 |
| 11 Jun 2023 | 2 | 33 | 58 | 19 |
| 18 Jun 2023 | 2 | 35 | 73 | 28 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 1,108 |
|---|---|
| Oct 2023 | 1,006 |
| Nov 2023 | 1,153 |
| Dec 2023 | 1,330 |
| Jan 2024 | 1,398 |
| Feb 2024 | 1,319 |
| Apr 2024 | 1,457 |
| May 2024 | 1,235 |
| Jun 2024 | 1,119 |
| Jul 2024 | 901 |
| Sep 2023 | 59,337 |
|---|---|
| Oct 2023 | 59,337 |
| Nov 2023 | 59,337 |
| Dec 2023 | 61,412 |
| Jan 2024 | 61,412 |
| Feb 2024 | 63,370 |
| Mar 2024 | 63,370 |
| Apr 2024 | 63,370 |
| May 2024 | 63,370 |
| Jun 2024 | 66,015 |
| Jul 2024 | 66,015 |
Novo Nordisk A/S other data
5.83%
+0.22%
of NVO is owned by hedge funds
870
+8
134.27M
+2.93M
shares is hold by hedge funds
| Patent |
|---|
Grant Filling date: 1 Oct 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 20 Aug 2018 Issue date: 13 Sep 2022 |
Application SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID Filling date: 6 Aug 2020 Issue date: 8 Sep 2022 |
Application SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST, AN SGLT2 INHIBITOR AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID Filling date: 6 Aug 2020 Issue date: 25 Aug 2022 |
Application Filling date: 22 Jul 2020 Issue date: 25 Aug 2022 |
Application Filling date: 27 Aug 2019 Issue date: 25 Aug 2022 |
Application Filling date: 5 Jun 2020 Issue date: 18 Aug 2022 |
Application Filling date: 14 May 2020 Issue date: 18 Aug 2022 |
Application Filling date: 10 Jul 2020 Issue date: 11 Aug 2022 |
Application Filling date: 19 Feb 2020 Issue date: 11 Aug 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 3 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 31 Jan 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Lars Fruergaard Jorgensen (1966) Pres, Chief Executive Officer & Member of Management Board | $5,420,000 |
Mr. Henrik Ehlers Wulff (1970) Executive Vice President, Head of Product Supply, Quality & IT and Member of the Management Board | $2,110,000 |
Ms. Camilla Sylvest (1972) Executive Vice President, Head of Commercial Strategy & Corporation Affairs and Member of the Management Board | $2,010,000 |
Mr. Karsten Munk Knudsen (1971) Executive Vice President, Chief Financial Officer & Member of the Management Board | $2,010,000 |
Ms. Monique Carter (1973) Executive Vice President, Head of People & Organisation and Member of Management Board | $1,520,000 |
Viking Therapeutics: Still On Track
Novo Nordisk: Negative Streak Finally Ended
GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?
Novo Nordisk's Loss Is Eli Lilly's Gain, And Vice Versa
It's Time To Be All-In On Novo Nordisk
A Cure For Novo Nordisk
Novo Nordisk: The Falling Knife That Keeps Giving
Industry Analysis: Pharmaceuticals Like Novo Nordisk Offer Long-Term Opportunities
What To Do With These Seven Stocks After They Plunged
-
What's the price of Novo Nordisk A/S stock today?
One share of Novo Nordisk A/S stock can currently be purchased for approximately $54.32.
-
When is Novo Nordisk A/S's next earnings date?
Novo Nordisk A/S is estimated to report earnings on Wednesday, 5 Nov 2025.
-
Does Novo Nordisk A/S pay dividends?
Yes, Novo Nordisk A/S pays dividends and its trailing 12-month yield is 1.65% with 47% payout ratio. The last Novo Nordisk A/S stock dividend of $0.39 was paid on 25 Aug 2021.
-
How much money does Novo Nordisk A/S make?
Novo Nordisk A/S has a market capitalization of 370.95B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 31.26% to 232.26B US dollars. Novo Nordisk A/S earned 83.68B US dollars in net income (profit) last year or $0.9 on an earnings per share basis.
-
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S is traded on the NYSE under the ticker symbol "NVO".
-
What is Novo Nordisk A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Novo Nordisk A/S?
Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the following people:
- Mr. Lars Fruergaard Jorgensen Pres, Chief Executive Officer & Member of Management Board(age: 59, pay: $5,420,000)
- Mr. Henrik Ehlers Wulff Executive Vice President, Head of Product Supply, Quality & IT and Member of the Management Board(age: 55, pay: $2,110,000)
- Ms. Camilla Sylvest Executive Vice President, Head of Commercial Strategy & Corporation Affairs and Member of the Management Board(age: 53, pay: $2,010,000)
- Mr. Karsten Munk Knudsen Executive Vice President, Chief Financial Officer & Member of the Management Board(age: 54, pay: $2,010,000)
- Ms. Monique Carter Executive Vice President, Head of People & Organisation and Member of Management Board(age: 52, pay: $1,520,000)
-
How many employees does Novo Nordisk A/S have?
As Jul 2024, Novo Nordisk A/S employs 66,015 workers, which is 4% more then previous quarter.
-
When Novo Nordisk A/S went public?
Novo Nordisk A/S is publicly traded company for more then 44 years since IPO on 30 Apr 1981.
-
What is Novo Nordisk A/S's official website?
The official website for Novo Nordisk A/S is novonordisk.com.
-
How can i contact Novo Nordisk A/S?
Novo Nordisk A/S can be reached via phone at +45 44 44 88 88.
-
What is Novo Nordisk A/S stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Novo Nordisk A/S in the last 12 months, the avarage price target is $158. The average price target represents a 190.86% change from the last price of $54.32.
Novo Nordisk A/S company profile:
Novo Nordisk A/S
novonordisk.comExchange:
NYSE
Full time employees:
71,880
Industry:
Biotechnology
Sector:
Healthcare
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Allé 1
Bagsvaerd, 2880
Bagsvaerd, 2880
CIK: 0000353278
ISIN: US6701002056
CUSIP: 670100205
